NCI's Division of Cancer Prevention is a leading participant for a key initiative in the National Institutes of Health (NIH) Glycoscience Common Fund program. This program supports development of accessible and affordable new tools and technologies for studying the role complex carbohydrates in health and disease.
The breakthroughs coming from this trans-NIH program will enable researchers in all biomedical fields to dramatically advance understanding of the roles of these complex molecules by providing accessible tools necessary for the examination of carbohydrate structure and function. The Glycoscience Common Fund program has plans to develop:
- methods and technologies for synthesis of biomedically relevant complex carbohydrates;
- accessible tools/technologies to analyze or manipulate carbohydrates and their binding partners; and
- glycomic data integration and analysis tools.
Karl Krueger, Ph.D., a program director within the NCI Division of Cancer Prevention's Cancer Biomarkers Research Group, leads the initiatives for tools development. Awards funded by these initiatives use the U01 mechanism for projects that are mature and ready to offer much needed cutting-edge technologies or reagents to the research community and the NCI-supported programs, such as NCI's Alliance of Glycobiologists. The U01s for tools development are administered through the NCI with project scientist oversight served by a program director from participating institutes with relevant expertise for each project.
Funding Opportunities for this Program
Facile Methods and Technologies for Synthesis of Biomedically Relevant Carbohydrates (U01) https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-15-007.html (closes October 15, 2015)
Novel and Innovative Tools to Facilitate Identification, Tracking, Manipulation, and Analysis of Glycans and their Functions (R21) https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-15-008.html (U01) https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-15-009.html (closes October 15, 2015)
The NIH Common Fund is a congressionally mandated program to support cross-cutting science expected to have exceptionally high impact in biomedical research. All Common Fund initiatives invite investigators to develop bold, innovative, and often risky approaches to address problems that may seem intractable, or to seize new opportunities that offer potential for rapid progress.